Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Significant Drop in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 3,807 shares, a drop of 42.4% from the September 15th total of 6,607 shares. Based on an average daily volume of 63,910 shares, the short-interest ratio is presently 0.1 days. Currently, 0.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Regentis Biomaterials Stock Performance

RGNT traded down $0.06 during trading hours on Friday, hitting $1.49. 23,490 shares of the company’s stock were exchanged, compared to its average volume of 63,331. Regentis Biomaterials has a 1-year low of $1.23 and a 1-year high of $15.50. The stock’s 50-day moving average is $1.90 and its two-hundred day moving average is $2.49.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last issued its quarterly earnings results on Friday, September 11th. The company reported ($0.22) EPS for the quarter.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is an Israel-based biotechnology company focused on developing biomaterial-based solutions for the repair and regeneration of damaged cartilage. The company’s work is aimed primarily at orthopedic applications, including the treatment of focal cartilage defects in the knee.

Regentis’ lead product is GelrinC, a synthetic, cell-free hydrogel implant designed to fill cartilage lesions and support the formation of new tissue. The implant is intended to be delivered during a minimally invasive procedure and gradually integrate with the surrounding joint environment as the repair process progresses.

The company’s activities center on research, clinical development, regulatory advancement and potential commercialization of its cartilage-repair technology.